Swedish biotech Alligator Bioscience has agreed to sell its CD40-targeting cancer immunotherapy mitazalimab to Canadian drug developer Biossil for $750,000 (€670,000) upfront, with up to $108 million (€97 million) in contingent milestones and additional royalties. The deal follows Alligator’s decision in July to discontinue independent development of the drug and concentrate its resources on another oncology program.
Mainz Biomed NV may have taken a major step in early pancreatic cancer detection. The company reports that its multivariate RNA liquid biopsy test, licensed from Liquid Biosciences Inc. in March, achieved 100% sensitivity and 95% specificity in a feasibility study. The results suggest the test could detect cancer—and even precancerous lesions—earlier than current methods.
Molecular diagnostics specialist Mainz Biomed NV has inked a research collaboration with precision microbiome firm Microba Life Sciences Inc.
BioMed NV